United Therapeutics Corp. (UTHR) is a company that develops and commercializes treatments for chronic diseases. One of the leading treatments is Remodulin which is used to reduce the symptoms related to pulmonary arterial hypertension. Under Remodulin, the company produces several drugs to enhance the exercise ability of PAH patients such as Tyvaso, Orenitram, Unituxin, and Adcirca. The company is also engaged in the development of Unexisome for treating bronchopulmonary dysplasia, various organ-transplant technologies.
The price of UTHR stock during the regular trading on January 10, 2022, with a slight increase of 0.15% was $199.24. At last check in the aftermarket, the stock was further significantly up by 5.40%.
UTHR: Events and Happenings
On December 30, 2021, UTHR reported that the company’s Executives presented the overview and updates on its business with the J.P. Morgan biotech expert held virtually on January 6, 2022. On December 3, 2021, UTHR reported that the company had been named as one of the Most Responsible Companies of US, 2022. The company received the award from the world-renowned stats portal Newsweek and Statista Inc.
UTHR: Key Financials
On November 3, 2021, UTHR reported its financial results for the quarter ended September 30, 2021. Some of the main highlights are as follows
Revenue
Total revenue during the third quarter of 2021 was reported to be $444.7 million as compared to $380.1 million for the same quarter of 2020. The total revenue grew 17% over the year.
Net Income per Share
Net income for Q3 2021 was $162.7 million or $3.62 per share (basic) and $3.42 (diluted) per share. While the income saw a drop of 7% over the year as it was $171 million or $3.86 (basic) per share and $3.84 per share (diluted) for the same quarter prior year.
On November 1, 2021, UTHR reported that the company’s Executives presented at the Virtual 30th Annual Credit Suisse Healthcare Conference held on November 8, 2021. On October 27, 2021, UTHR reported about the expansion of its collaboration with 3D Systems. The collaboration combined 3D printing technology with the regenerative medicine and organ manufacturing technology of UTHR. The companies were focused on printing the scaffolds for the lungs of humans using the Print to Perfusion technique. The aim of the partnership is that patients with end-stage lung disease may receive transplants for an active lifestyle.
On October 21, 2021, UTHR reported that its data on pulmonary arterial hypertension and pulmonary hypertension related to interstitial lung disease was presented at the annual meeting of the American College of Chest Physicians commonly known as CHEST 2021.
Conclusion
The stock of UTHR is 7% up to as compared to the past six months despite the challenges faced by the economy due to the pandemic situation. The company’s strong stock background reflects its investor-centered policies. The analysts are suggesting that the stock is in good form to attract more and better investment options from stockholders.
